| Document |
Document Title |
|
WO/2022/039190A1 |
The objective of the present invention is to provide an inexpensive and effective sirtuin activating substance derived from a natural product. Said objective of the present invention can be achieved by: a sirtuin activator including β...
|
|
WO/2022/039215A1 |
[Problem] To provide a novel technique capable of inhibiting muscle breakdown. [Solution] A muscle breakdown inhibitor containing glycerol phosphoric acid, a salt thereof, and/or a polymer of these.
|
|
WO/2022/036629A1 |
A method for preparing a phloroglucinol injection, the method comprising: (1) mixing trimethylphloroglucinol and phloroglucinol according to a mass ratio of 1:9, and crushing same; (2) taking sodium chloride, and adding same to the foreg...
|
|
WO/2022/037537A1 |
A stable pharmaceutical composition, belonging to the technical field of medicine. The pharmaceutical composition having active ingredients of edaravone and dextrocamphol can surprisingly control the content of unique impurity SCR-756 an...
|
|
WO/2022/035115A1 |
The present invention relates to a composition for the prevention and treatment of skeletal muscle-related diseases, containing an Alnus japonica extract or a compound isolated therefrom as an active ingredient. With respect to Alnus jap...
|
|
WO/2022/034912A1 |
The present invention provides an anti-human TRPV2 antibody, which recognizes an extracellular domain of human TRPV2 as an epitope, or a fragment thereof.
|
|
WO/2022/033303A1 |
The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer...
|
|
WO/2022/032484A1 |
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof....
|
|
WO/2022/033525A1 |
Provided is a method of extending lifespan and/or anti-aging in a subject, comprising the step of administering to the subject an effective amount of a preparation of young and undamaged human serum albumin (HSA), wherein the preparation...
|
|
WO/2022/035220A1 |
The present invention relates to a composition for preventing, improving or treating muscle weakness-related muscle diseases, comprising a chestnut flower extract as an active ingredient. The composition is effective in the amelioration ...
|
|
WO/2022/028472A1 |
A nucleic acid comprising a first nucleic acid region comprising a nucleic acid sequence encoding a SMN protein or variant thereof; and a second nucleic acid region comprising one or more target segment(s) of one or more endogenous micro...
|
|
WO/2022/030606A1 |
A compound represented by general formula (I) or a salt thereof; a nerve growth promoter containing the compound or salt as the active ingredient; a medicinal composition containing the compound or salt; a therapeutic agent for neurodege...
|
|
WO/2022/027237A1 |
An application of quizartinib as a necroptosis inhibitor. An application of quizartinib as an RIPK1-dependent cell necroptosis inhibitor. An application of quizartinib as a cell necroptosis initiation marker phosphorylation inhibitor, th...
|
|
WO/2022/030719A1 |
The present invention relates to a novel use of rose hip as ground rose hip or a rose hip extract, and to a composition for improving, treating, or preventing muscle disease, or improving muscle function, containing rose hip as an active...
|
|
WO/2022/028547A1 |
Provided in the present invention are a class of bifunctional compounds for targeting and degrading an IRAK4 kinase protein, a pharmaceutical composition and a preparation method therefor. The compound of the present invention can not on...
|
|
WO/2022/027240A1 |
An application of primidone as a RIPK1 inhibitor. Primidone can be used as a RIPK1 inhibitor to treat amyotrophic lateral sclerosis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, ischemia-reperfusion injury, ischemic s...
|
|
WO/2022/022472A1 |
Use of a nicotinamide nucleoside triaryl formate compound and a composition thereof in increasing the level of coenzyme I (NAD) in a human body, improving a health condition or treating a related disease, and a compound of formula (II-1)...
|
|
WO/2022/025468A1 |
The present invention relates to a composition comprising Gryllus bimaculatus, more specifically, a Gryllus bimaculatus powder or a protein extract of Gryllus bimaculatus as an active ingredient for prevention, alleviation, or treatment ...
|
|
WO/2022/025493A1 |
The present invention provides a pharmaceutical composition comprising mesenchymal stem cells for treatment or prevention of myofibrosis. In addition, the present invention provides a pharmaceutical composition for treatment or preventio...
|
|
WO/2022/023792A1 |
The invention provides a method of treating an idiopathic inflammatory myopathy in a human patient by administering an anti-CD26 antibody.
|
|
WO/2022/025456A1 |
The present invention relates to a composition for diagnosing musculoskeletal diseases and a composition for preventing or treating musculoskeletal diseases. Zkscan 8, which is presented in the present invention, is effectively usable as...
|
|
WO/2022/024034A1 |
Provided herein are antigen binding proteins that specifically bind to BMP1, TLL1 and/or TLL2. Also provided are pharmaceutical compositions containing the antigen binding proteins. The antigen binding proteins and pharmaceutical composi...
|
|
WO/2022/025783A1 |
The invention relates to genetic engineering, biotechnology and medicine; more specifically, the present invention provides stimulation of angiogenesis, regeneration of nerve fibers of blood vessels and regeneration of skeletal muscle by...
|
|
WO/2022/024385A1 |
The populations of industrialized countries around the world are rapidly aging. In order for aged individuals to stay healthy both physically and mentally, the maintenance of muscle mass and bone mass is instrumental; however, aged indiv...
|
|
WO/2022/025148A1 |
Provided are: a new miR-96-5p inhibitor that is more effective than an antisense oligonucleotide against miR-96-5p; and a pharmaceutical composition containing same. The miR-96-5p inhibitor includes a peptide nucleic acid portion havin...
|
|
WO/2022/022617A1 |
Provided herein are methods and compositions related to combinations of (a) agents that increase the expression of SMN2 gene or protein, and (b) modulators of SMN2 mRNA splicing or stability that increase the production of functional SMN...
|
|
WO/2022/020108A1 |
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on m...
|
|
WO/2022/020616A1 |
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specifi...
|
|
WO/2022/020107A1 |
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on m...
|
|
WO/2022/018297A1 |
The present invention relates to the use of Alverine or one of its derivatives for treating diseases associated with mitochondrial dysfunction, especially with mitochondrial complex I deficiency.
|
|
WO/2022/014703A1 |
In the present invention, a myoregulin inhibitor such as a myoregulin antisense oligonucleotide or anti-myoregulin antibody is employed as an active component of an agent for preventing or treating a muscular disease such as muscular dys...
|
|
WO/2022/014604A1 |
The present invention provides a composition that is for treating myogenic diseases and that contains a cell group including skeletal muscle precursor cells differentiation-induced from pluripotent stem cells, the composition being chara...
|
|
WO/2022/015753A1 |
The present disclosure relates compositions and methods to treat neuromuscular diseases and disorders, e.g., spinal muscular atrophy (SMA), characterized by the presence of a splicing silencer located in SMN2 intron 7 pre-mRNA, comprisin...
|
|
WO/2022/007875A1 |
The present invention relates to the use of a compound of formula (I) or a pharmacologically acceptable salt, a stereoisomer, an active metabolite, a prodrug, a crystal or a solvate thereof or a composition thereof in the preparation of ...
|
|
WO/2022/011155A1 |
The present invention includes a method of predicting and/or treating a recurrence of MS treating a patient with multiple sclerosis, the method comprising: obtaining a hematopoietic cell sample from a patient suspected of having a recurr...
|
|
WO/2022/009698A1 |
The present invention provides a peptide that has high myostatin inhibition activity and that has improved stability in vivo. A peptide represented by formula (1) in the description.
|
|
WO/2022/010834A1 |
Disclosed are methods of treating a subject, such as those having or at risk of cardiomyopathies, with an effective amount of a recombinant adeno-associated virus (rAAV) virion, the rAAV virion comprising an AAV capsid and an expression ...
|
|
WO/2022/003673A1 |
The present invention provides novel peptide analogs of Humanin, pharmaceutical composition comprising the peptides and uses thereof for treating diseases, disorders or conditions associated with mitochondrial dysfunction, such as but no...
|
|
WO/2022/004788A1 |
The present invention addresses the problem of providing an ameliorating agent or a prophylactic agent for a muscle weakness symptom in a disease or a syndrome associated with a metabolic disorder. The present invention provides an ameli...
|
|
WO/2022/004816A1 |
Provided is a cranial nerve disorder therapeutic agent that includes, as an active ingredient, a culture supernatant of tissue cells derived from a fetal appendage.
|
|
WO/2022/004765A1 |
A polyion complex including a block copolymer that has a cationic polymer block and a hydrophilic polymer block, an mRNA that encodes a Cas protein, and a guide RNA. A composition for genome editing including the polyion complex, and a p...
|
|
WO/2022/002225A1 |
Provided are an indole derivative as shown in general formula (I-1) and use thereof in preparing a drug used for preventing and/or treating indications for disorders related to an S1P receptor. The indole derivative is respectively subst...
|
|
WO/2022/003623A1 |
The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spa...
|
|
WO/2021/261707A1 |
The present invention relates to a composition for alleviating, treating, or preventing muscular diseases, or improving muscular functions, containing, as an active ingredient, a Korean mint extract or tilianin. Korean mint or tilianin a...
|
|
WO/2021/260731A1 |
The present invention discloses water-soluble 3-O-acetyl-11-keto-β-boswellic acid compositions comprising 3-O-acetyl-11-keto-β-boswellic acid in combination with a metal ion selected from potassium or sodium in the form of respective m...
|
|
WO/2021/262765A1 |
The present disclosure provides compositions and methods based on the inhibition of thrombospondin-1 as a therapeutic target in aging skeletal muscle to improve muscle mass, strength, function, maintenance, and regeneration.
|
|
WO/2021/261592A1 |
Provided are: a repeat binding agent containing a cyclic pyrrole-imidazole polyamide that targets a repetitive sequence that includes A or T and that causes repeat diseases; and a pharmaceutical composition containing said binding agent.
|
|
WO/2021/258159A1 |
The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular d...
|
|
WO/2021/261571A1 |
The present invention pertains to a vascular endothelial cell protecting agent, a blood-cerebrospinal fluid barrier protecting agent, and a central nervous system protecting agent, comprising at least one compound selected from the group...
|
|
WO/2021/260379A1 |
The present invention relates to methods for treating facioscapulohumeral dystrophy (FSHD). Specifically, the invention relates to the use of an inhibitor of necroptosis for treating FSHD.
|
